RA Capital Management’s EyePoint Pharmaceuticals EYPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,181,818
| Closed | -$17.2M | – | 71 |
|
|
2025
Q1 | $17.2M | Hold |
3,181,818
| – | – | 0.29% | 46 |
|
|
2024
Q4 | $23.7M | Buy |
+3,181,818
| New | +$23.7M | 0.32% | 53 |
|
|
2024
Q2 | – | Sell |
-938,591
| Closed | -$19.4M | – | 83 |
|
|
2024
Q1 | $19.4M | Buy |
+938,591
| New | +$19.4M | 0.25% | 59 |
|
|
2023
Q4 | – | Sell |
-3,370,506
| Closed | -$26.9M | – | 66 |
|
|
2023
Q3 | $26.9M | Hold |
3,370,506
| – | – | 0.53% | 47 |
|
|
2023
Q2 | $29.3M | Hold |
3,370,506
| – | – | 0.55% | 42 |
|
|
2023
Q1 | $9.91M | Hold |
3,370,506
| – | – | 0.22% | 52 |
|
|
2022
Q4 | $11.8M | Hold |
3,370,506
| – | – | 0.24% | 51 |
|
|
2022
Q3 | $26.7M | Hold |
3,370,506
| – | – | 0.57% | 48 |
|
|
2022
Q2 | $26.5M | Hold |
3,370,506
| – | – | 0.71% | 39 |
|
|
2022
Q1 | $41M | Hold |
3,370,506
| – | – | 0.89% | 36 |
|
|
2021
Q4 | $41.3M | Buy |
3,370,506
+1,160,000
| +52% | +$14.2M | 0.73% | 40 |
|
|
2021
Q3 | $23M | Buy |
2,210,506
+960,506
| +77% | +$10M | 0.32% | 59 |
|
|
2021
Q2 | $11.2M | Hold |
1,250,000
| – | – | 0.18% | 69 |
|
|
2021
Q1 | $12.7M | Buy |
+1,250,000
| New | +$12.7M | 0.19% | 65 |
|
|
2014
Q3 | – | Sell |
-255,566
| Closed | -$11.1M | – | 46 |
|
|
2014
Q2 | $11.1M | Hold |
255,566
| – | – | 1.12% | 17 |
|
|
2014
Q1 | $10.5M | Buy |
255,566
+136,805
| +115% | +$5.61M | 0.75% | 22 |
|
|
2013
Q4 | $4.72M | Buy |
+118,761
| New | +$4.72M | 0.55% | 22 |
|